Purpose Nitazoxanide was recently reported as having in vitro effectiveness against the rubella virus. Immunodeficiency-related vaccine-derived rubella occurs in some patients who have an inherited immunodeficiency and who received the MMR vaccine. This study investigated the in vivo effectiveness of nitazoxanide therapy. Methods This is a retrospective analysis of seven patients treated with nitazoxanide as salvage therapy for immunodeficiency-related vaccine-derived rubella infection. The patients were recruited from an ongoing rubella detection surveillance project.
Introduction
Rubella virus is a single-stranded RNA virus and is an important human pathogen because of its ability to cause fetal malformations during in utero infection [1] . It is not thought to represent a dangerous pathogen for immunocompetent adults, although persistent infections in immune-privileged body sites have been described. Indeed, rubella-associated arthritis/arthralgia can develop in adults due to persistent vaccine-strain infection [2] . Fuch's uveitis is also associated with persistent infection with rubella virus, and a few cases of uveitis have been observed with vaccine-strain rubella [3, 4] . These cases demonstrate the ability of the rubella virus to evade immune eradication/control even in immunocompetent individuals although the reasons for this are not defined. Recently, patients with primary immunodeficiency have been identified with persistence of vaccine-strain rubella associated with chronic inflammation [5, 6] . Immunodeficiency-related vaccine-derived rubella virus (iVDRV) was initially identified in patients with cutaneous granulomas. More recently, iVDRV has been detected in other sites of chronic inflammation [5, 6] .
To date, there are no known treatments that are highly effective. In most cases, the inflammation has progressed relentlessly unless hematopoietic stem cell transplantation (HSCT) has been performed with resolution of the immunodeficiency, although one patient has been reported to have responded to topical steroid treatment [7] . Rubella virus is insensitive to type I interferons and no other antiviral therapy is of proven benefit. The inability of specific maternal and fetal antibody to clear rubella virus infection in the fetus also suggests that humoral immunity alone is not sufficient in eliminating the persisting virus [8] . Thus, most of the tools utilized for chronic viral infections in immunodeficient patients are not thought to be effective for rubella virus.
Rubella virus replication can be inhibited in vitro with the drug nitazoxanide [9] . Nitazoxanide is approved for the treatment of parasites, protozoa, and anaerobic bacteria. It has been demonstrated to have antiviral activities and is being tested as a therapeutic intervention for hepatitis C, influenza, rotavirus, and norovirus. Nitazoxanide has a favorable adverse event profile and is used frequently in children for the treatment of parasitic disease. The mechanism of its anti-viral action is not understood but it may act in a cell-intrinsic fashion to limit replication. We recently demonstrated that nitazoxanide inhibited rubella virus replication in human umbilical vein endothelial, Vero, and A549 cells [9] . The inhibitory concentration was consistent with serum levels obtained during therapeutic use. Analysis of the effect of nitazoxanide revealed multiple mechanisms of inhibition at both early and late stages of infection. We therefore retrospectively analyzed the effect of nitazoxanide treatment in a case series of immunodeficient patients with persistent iVDRV at our institutions.
Methods
For this study, seven patients with a primary immunodeficiency and persistent iVDRV were identified. Ongoing surveillance for iVDRV in the USA at the CDC and in France at the Institut Pasteur for rubella capsid and genome [5, 6] led to definition of the initial iVDRV cohort and submitting physicians identified nitazoxanide use. Based on in vitro efficacy, limited adverse events, poor prognosis, and absence of other proven interventions, clinicians at each site decided to institute therapy with nitazoxanide. This is a retrospective study of outcomes of the seven patients. A structured case report form was used to collect standardized data from each physician. No statistical analysis was performed.
Results
All patients had a significant T cell-oriented immunodeficiency and most had low T cell counts in peripheral blood (Table 1 ). Only patients 3 and 4 had normal T cell counts. T cell function was not systematically assessed. Natural killer cell counts (NK cells) were generally normal. The age of onset of inflammatory lesions ranged from 15 months of age to 16 years, and all patients had previously received the MMR vaccine months to years prior to symptoms. All patients had skin involvement that was described as initially psoriasiform or resembling pyoderma gangrenosum (Fig. 1) . The cutaneous granulomas spread relentlessly and in one case led to amputation and in another case led to surgical excision in an effort to control the spread. Neither effort at surgical control of the lesions was successful. Empiric treatments directed at mycobacteria or fungi were not successful. Immune suppression appeared to help in two cases but did not lead to resolution. In the most severe cases, multiple organs were ultimately affected. Rubella capsid protein was detected in all patients, and virus RNA was recovered from patients 2, 4, and 5. Different iVDRV strains with multiple non-overlapping mutations were identified in the skin biopsies by sequencing viral genomes. Survival was generally dismal, and progressive multifocal leukoencephalopathy (PML) was the final cause of death in two patients. HSCT was curative in one patient with resolution of skin lesions. Immunoglobulin was used uniformly without benefit.
Nitazoxanide was used largely as salvage therapy in these extremely ill patients. Rubella capsid protein became undetectable (Fig. 2) in two patients (patients 4 and 5) but without clinical improvement although progression may have stabilized. In one case, clear clinical improvement coincided with the institution of nitazoxanide (patient 7). In the other four cases, nitazoxanide had no obvious benefit (Table 1) . 
Discussion
This study provides critical information on treatment approaches for clinicians caring for immunodeficient patients with this challenging complication. The recent identification of iVDRV in granulomatous inflammation has led to increasing recognition; however, there no known therapeutic approach. Nitazoxanide may have provided some limited benefit in our study. One patient had dramatic resolution, only to die later of PML (patient 7). Similarly, one patient may have stabilized with diminished rubella capsid detection, but this patient also succumbed to PML (patient 5). Patient 4 was thought have slowed in the progression of lesions but did not resolve any existing lesions. Our model of this condition describes an interplay between acquired mutations that allow escape from T cell control and compromised T cell function. We hypothesize that the administration of live attenuated vaccine rubella in patients with T cell compromise allows prolonged persistence. The additional time for replication allows the acquisition of mutations that favor persistence in M2 macrophages. The acquired mutations further facilitate escape from T cell control. If nitazoxanide is beneficial, it may require a threshold of competent T cells, may require longer treatments, or it may be effective against iVDRV strains that have There is no detectable rubella capsid specific replication characteristics. These data do not provide strong support for efficacy of nitazoxanide as salvage therapy; however, the drug has limited adverse events and may provide limited benefit. The question of whether it might provide more clinical effectiveness earlier in the infection is unanswered. This study also highlights a second finding. The patients who are susceptible to iVDRV are extremely immunodeficient. Definitive treatment with HSCT had not been performed in these patients for a variety of reasons, but is underway for patient 3 (currently d + 140) and may provide the only curative strategy. The poor outcomes in this study document the uphill battle faced by patients with combined immunodeficiency who are not transplanted [10] . Out of two long-term survivors in this small study, one had an HSCT and the second one is 18 years old at the time of this report and is clinically stable but with ongoing inflammatory iVDRV disease.
Conclusions
In summary, nitazoxanide may have provided some benefit in 3/7 patients with persistent iVDRV. Additional study may define the variables related to responsiveness.
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